Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the phenylpyrazole class of organic compounds. It features a pyrazolo[3,4-d]pyrimidinone core substituted with a 2,4,6-trichlorophenyl group and a 3,4-dihydroxybenzyl moiety. The drug is experimental with no publicly available detailed mechanism of action or clinical indication information. Its chemical structure suggests potential for biological activity related to kinase inhibition or other enzyme modulation typical for pyrazolopyrimidine derivatives; however specific targets and therapeutic uses are not documented in available sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-(3,4-dihydroxybenzyl)-3-ethyl-1-(2,4,6-trichlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4(5H)-one.